Across 89 European CTIS diabetes Phase II/III trials from 2024–2026, CROs or CRO-like operational vendors were listed in 42/89 trials (47.2%). IQVIA / Q² Solutions was the most active group with 19 CRO-supported trials, followed by ICON with 14. CRO demand is highest when diabetes trials cross major CTIS-country and site thresholds: 11+ country trials were 6/6 CRO-supported, and 21+ site trials were 23/25 CRO-supported.
Among 89 diabetes Phase II/III trials, 42/89 (47.2%) reported CRO involvement. IQVIA / Q² Solutions appeared in 19/42 CRO-supported trials (45.2%), followed by ICON in 14/42 (33.3%).
The active vendor landscape is led by global CRO groups and specialist trial-infrastructure providers rather than one full-service CRO alone. IQVIA / Q² and ICON stand out, but 4G Clinical, Labcorp, Clario/Perceptive, Syneos, Almac and Celerion show that diabetes outsourcing is distributed across laboratories, digital systems, trial logistics, and operational support.
CRO involvement rises sharply with CTIS country and site footprint: single-country studies used CROs in 7/46 trials (15.2%), while 11+ country studies used CROs in 6/6 trials (100.0%). Site burden shows the same pattern, from 2/34 (5.9%) at 1–5 sites to 23/25 (92.0%) at 21+ sites.
The practical CRO trigger in diabetes is not phase alone; it is operational spread. Once a trial crosses multi-country CTIS submission, multi-site activation, or several hundred participants, outsourcing becomes the default operating model rather than an optional add-on.
CRO use was highest in diabetic retinopathy or macular edema trials at 7/9 (77.8%), obesity or overweight with diabetes at 10/13 (76.9%), and cardiorenal comorbidity at 8/11 (72.7%). Type 1 diabetes was lower at 7/24 (29.2%).
CRO demand is strongest where diabetes intersects with specialist endpoints, cardiovascular or renal risk, ophthalmology, metabolic comorbidity, and larger regulatory programs. Smaller academic Type 1 diabetes and diabetic foot ulcer studies are less likely to list CRO support.
The most frequent outsourced function was central or special laboratory and bioanalysis support in 40/89 trials (44.9%). EDC/eCRF/data capture appeared in 28/89 (31.5%), IMP supply/logistics in 25/89 (28.1%), and clinical operations or monitoring in 24/89 (27.0%).
Diabetes outsourcing is not limited to classic monitoring. The largest recurrent needs are central labs, bioanalysis, data capture, clinical supply logistics, randomisation systems, eCOA/ePRO, patient reimbursement, and recruitment/retention infrastructure—especially when CTIS submissions span multiple countries.
CRO-supported trials had a median of 4.5 CTIS countries, 29 sites, and 157 participants, compared with 1 country, 2.5 sites, and 80 participants in non-CRO trials. Dose-escalation or multi-dose-combined designs used CROs in 11/13 trials (84.6%).
CRO-supported diabetes trials are materially broader and more operationally complex. The strongest signal is site and CTIS-country load, reinforced by randomisation systems, laboratory work, supply logistics, and dose-level management.
The dataset contains 283 CTIS country-level records. Germany appeared in 39 country records, Poland in 32, France in 24, Italy in 22, and Spain in 20; by site burden, Poland led with 259 sites and 3,807 participants, followed by Germany with 200 sites and 2,343 participants.
| Germany | 39 |
| Poland | 32 |
| France | 24 |
| Italy | 22 |
| Spain | 20 |
| Czechia | 17 |
| Hungary | 15 |
| Slovakia | 14 |
| Country | Sites | Participants |
|---|---|---|
| Poland | 259 | 3,807 |
| Germany | 200 | 2,343 |
| Spain | 144 | 2,013 |
| France | 142 | 1,619 |
| Italy | 119 | 1,094 |
| Hungary | 115 | 854 |
| Czechia | 91 | 896 |
| Sweden | 65 | 562 |
For EU submission planning, Germany, Poland, France, Italy and Spain are the recurring diabetes execution anchors. CRO value is most visible in coordinating large Part II packages, site activation, local documents, vendor systems, patient logistics, and country-level operational follow-through.
The same CTIS dataset shows that Phase III trials used CROs in 26/47 cases (55.3%) versus 16/42 Phase II trials (38.1%), and multi-country diabetes trials used CROs in 35/43 cases (81.4%). Pharmaceutical-company sponsors accounted for 39/55 CRO-supported sponsor-type cases (70.9%), while hospital sponsors used CROs in 0/23 cases.
The strongest additional finding is commercial-sponsor concentration: CRO demand is heavily associated with pharma-led, multi-country, Phase III, and operationally complex programs. Academic or hospital-led diabetes studies are mostly smaller and less likely to list CRO support.
CTIS means Clinical Trials Information System. In this report, CTIS country records refer to country-level Part II submission, decision, site and participant entries in the provided dataset.
CRO means contract research organization or CRO-like operational vendor listed in the sponsor third-party and CRO fields.
EDC/eCRF means electronic data capture/electronic case report form; RTSM/IWRS means randomisation and supply management systems; eCOA/ePRO/DCT means electronic clinical outcome assessment, electronic patient-reported outcomes, and decentralized-trial support; IMP means investigational medicinal product.